Page 3 - Positive Phase News Today

Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine Results published today in the New England Journal of

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session  Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and seco...

Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking...

Positive Phase 3 Dupixent (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session Dupixent significantly improved skin

Asthma is considered to be one of the world's most common diseases affecting the population, and is also a life-threatening condition affecting patients'...

Twitter Inc (NYSE: TWTR) shares made a strong comeback in 2018, ending the year with nearly a 20-percent advance and outperforming social media peers. The short-messaging platform has built on the gains with a 14.4-percent advance in the first quarter of 2019. Thats smaller than Facebook,... Read More...

The FDA approved an expansion in the label for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SAs (NASDAQ: SNY) immunotherapy Libtayo for treating patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor, HHI, or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC. Moderna Strikes Vaccine Supply Agreements With Taiwan and Colum...

717.5 -3.8% (1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual...

(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Oper...